{"filings":[{"id":1207996,"accession_number":"0001193125-26-278647","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2026-06-23T14:14:09+00:00","items":["5.07"],"status":"ready","headline":"Agenus shareholders approve all six proposals at 2026 annual meeting, including option exchange","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Garo Armen and Jennifer Buell as Class II directors; Armen received 13.37M for, 6.12M withheld; Buell 13.91M for, 5.57M withheld.","Approved ESPP amendment increasing authorized shares from 150,000 to 200,000.","Approved amendment to 2019 Equity Incentive Plan adding 5,000,000 shares to the pool.","Approved one-time stock option exchange program with premium strike prices for directors and executive officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":470796,"accession_number":"0001193125-26-226693","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2026-05-15T20:08:27+00:00","items":["5.02"],"status":"ready","headline":"Agenus Inc. Principal Accounting Officer Austin Charette to resign effective May 29, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Austin Charette, Senior Director, Financial Reporting and Compliance and Principal Accounting Officer, resigning.","Resignation effective May 29, 2026; Charette informed the company on May 12, 2026.","No successor has been announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":29,"accession_number":"0001193125-26-215838","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2026-05-11T12:52:03+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agenus Q1 net income $39.2M, revenue $33.7M; SEC closes investigation with no action","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $39.2M vs loss of $26.4M in Q1 2025; total revenue $33.7M (+40% YoY).","Cash rose to $35.0M at March 31, 2026 from $3.0M at Dec 31, 2025, boosted by Zydus deal proceeds.","Zydus collaboration closed Jan 2026 providing $91M upfront; Phase 3 BATTMAN trial began enrolling in April.","SEC concluded its investigation with no enforcement action (May 2026); related class action dismissed in March."],"consensus_eps_estimate":2.142,"consensus_eps_actual":1.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":33736000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101275,"accession_number":"0001193125-26-125170","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Agenus wins dismissal of securities class action; court denies leave to amend","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["U.S. District Court for Massachusetts granted motion to dismiss entire securities class action against Agenus and four individual defendants.","Court ruled in favor of defendants and denied plaintiff's request to amend complaint.","Lawsuit alleged violations of federal securities laws related to public disclosures.","Case was Byron Olsen v. Agenus Inc., Garo H. Armen, et al., Civil Action No. 24-CV-12299-AK.","Dismissal removes a significant litigation overhang for the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101274,"accession_number":"0001193125-26-107288","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agenus reports $4.2M initial BOT+BAL revenue; net loss narrows to $3.1M in FY2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Pre-commercial product revenue of $4.2M from early access programs in France and paid NPP across 30+ countries.","BOT+BAL shows 42% two-year OS and ~21-month median OS in heavily pretreated MSS mCRC; Phase 3 BATTMAN trial initiated.","France AAC expanded to ovarian cancer and sarcoma in January 2026; 200+ physician inquiries received globally.","Zydus collaboration provided $91M upfront capital; $20M contingent payment triggered in March 2026 for manufacturing.","Q4 2025 operating income $14.4M; full year net loss $3.1M vs prior year; other revenue $110M (non-cash royalty)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101273,"accession_number":"0001193125-26-014678","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2026-01-16T23:59:59+00:00","items":["2.01","9.01","3.02","7.01"],"status":"ready","headline":"Agenus closes $141M strategic collaboration with Zydus; sells manufacturing, issues equity, licenses BOT/BAL","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Zydus pays $75M cash for Agenus' biologics manufacturing facilities in Emeryville and Berkeley, CA.","Zydus affiliate purchases 2,133,333 AGEN shares at $7.50 ($16M) in concurrent equity investment.","Agenus eligible for up to $50M in contingent payments based on BOT+BAL production orders over 36 months.","Exclusive license to Zydus for BOT and BAL in India and Sri Lanka; Agenus receives 5% royalty on net sales.","Pro forma shows estimated $37.5M gain on derecognition and net cash of ~$58.4M at closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101272,"accession_number":"0001193125-26-012922","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2026-01-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Agenus appoints CEO Garo Armen as interim CFO; names Austin Charette Principal Accounting Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Garo Armen, age 72, Chairman and CEO, appointed interim CFO and Principal Financial Officer effective Jan 8, 2026.","No new compensation arrangements for Armen; salary and bonuses continue to be paid in stock.","Austin Charette, 37, promoted from Senior Director, Financial Reporting to Principal Accounting Officer effective same date.","Charette joined Agenus in 2017 and previously served at Deloitte & Touche LLP.","Neither appointment is tied to any arrangement or family relationship with other officers or directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101271,"accession_number":"0001193125-26-007706","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["1.01","3.03"],"status":"ready","headline":"Agenus lowers warrant exercise price to $7.50; Ligand releases liens on assets","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Modified warrant exercise price from $17.30 to $7.50 per share as part of Amendment Agreement with Ligand.","Ligand released liens on certain of Agenus' assets in exchange for the reduced warrant price.","Agreement executed Jan 3, 2026; full terms will be filed in upcoming 10-K.","The modification is dilutive to existing shareholders if warrant is exercised."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117633,"accession_number":"0001193125-25-273266","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agenus reports Q3 net income on MiNK gain; France reimburses BOT/BAL access","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["France authorizes reimbursed compassionate access for BOT/BAL in refractory MSS mCRC; patients under treatment.","BOT/BAL shows 42% two-year OS, 20.9-month median OS in 123 heavily pretreated MSS mCRC patients.","Phase 3 BATTMAN trial initiated Q4 2025 across 100+ sites in Canada, France, Australia, NZ.","MiNK deconsolidation generates ~$100.9M gain; net income for Q3 and nine-month periods.","Zydus provides $10M bridge facility ahead of $91M closing; equity at $7.50/share."],"consensus_eps_estimate":2.0196,"consensus_eps_actual":0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":79992000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117632,"accession_number":"0001193125-25-235819","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Agenus enters $10M promissory note with Zydus; bears 3.81% interest, secured by 822,910 INKT shares","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Up to $10M note at 3.81% p.a.; matures at APA/SPA closing or 10 days after notification that closing will not occur.","Proceeds fund Q4 2025 operational expenses of Emeryville and Berkeley facilities; forgiven if APA/SPA closes.","Collateral: 822,910 shares of MiNK Therapeutics (NASDAQ: INKT); control agreement provides Zydus rights upon default.","Bridge financing tied to pending Zydus asset purchase; facility expense amounts forgiven if deal closes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134069,"accession_number":"0001193125-25-213574","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2025-09-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Agenus and Zydus CFIUS review shifts closing to Q4 2025 after full notice request","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CFIUS requested voluntary full notice submission for Agenus-Zydus transactions on September 17, 2025.","Transactions involve asset purchase of manufacturing ops, minority stock purchase, and BOT/BOL license in India and Sri Lanka.","Anticipated closing delayed to Q4 2025 due to CFIUS review timeline.","No material change to deal terms; previously announced June 3, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134068,"accession_number":"0000950170-25-106235","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agenus Q2 net loss improves; Zydus deal adds $91M; BOT/BAL Phase 3 starts Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $25.7M; YTD net loss $56.4M vs $118.3M YoY; cash burn reduced to $45.8M from $76.4M.","Zydus collaboration closing Q3 2025; $91M upfront capital to support development and regulatory activities.","BOT/BAL: 42% two-year survival in refractory MSS CRC; FDA agreed to streamlined Phase 3 (BATTMAN) starting Q4 2025.","Virtual stakeholder meeting on August 27, 2025 to review Q2 results and strategic progress.","Noetik AI partnership started to refine patient selection via AI algorithms."],"consensus_eps_estimate":1.3804,"consensus_eps_actual":-2.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":49757000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150817,"accession_number":"0000950170-25-088502","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Agenus shareholders reject one-time option exchange and say-on-pay at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Directors Corvese and Wright elected with ~5.99M and ~6.86M for votes respectively.","Equity plan increases approved: EIP from 5.05M to 12.05M shares; other plans also raised.","Proposal 5 (option exchange) not approved: 4.87M for, 5.82M against, 5.89M broker non-votes.","Proposal 6 (say-on-pay) not approved: 5.16M for, 5.18M against, 0.47M abstain.","KPMG ratification passed with 13.62M for versus 2.87M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150816,"accession_number":"0000950170-25-081674","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Agenus sells manufacturing assets to Zydus for $75M upfront; license BOT/BAL in India","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Asset sale of Emeryville/ Berkeley CA facilities for $75M at closing; up to $50M additional contingent payments.","Exclusive license to Zydus for BOT/BAL in India and Sri Lanka; 5% royalty on net sales.","Zydus makes $16M equity investment at $7.50/share (approx. 2.1M shares); 12-month lockup.","Transaction includes contract manufacturing agreement; proceeds to fund BOT/BAL development.","Parties aim to close within 60 days, subject to customary conditions and government approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150815,"accession_number":"0000950170-25-068564","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agenus Q1 net loss $26.4M ($1.03/sh); cash burn reduced; BOT/BAL 100% pCR in dMMR CRC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2025 cash $18.5M (down from $40.4M Dec 2024); operating cash burn $25.6M vs $38.2M YoY.","Net loss $26.4M ($1.03/sh) narrowed from $63.5M ($3.04/sh) Q1 2024; revenue $24.1M (non-cash royalty).","On track to cut annualized cash burn below $50M in H2 2025; final stages of collaboration for cash infusion.","BOT/BAL showed 100% pCR in dMMR CRC at higher dose; NEOASIS study responses in TNBC, sarcomas; HCC durable.","Appointed Dr. Richard Goldberg as Chief Development Officer to lead BOT/BAL regulatory engagement."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":24066000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169757,"accession_number":"0000950170-25-036829","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agenus Q4 net loss $46.8M; targets annual cash burn of ~$50M by mid-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 net loss $46.8M ($2.04/share); full-year net loss $232.3M ($10.59/share).","Revenue Q4 $26.8M, full-year $103.5M (largely non-cash royalty).","Cash balance $40.4M at Dec 31, 2024, down from $76.1M year-end 2023.","Operational cash burn $28.7M in Q4; plan to cut annualized burn to ~$50M by mid-2025.","BOT/BAL program shows durable responses in colorectal cancer; partnership discussions ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169756,"accession_number":"0000950170-25-027947","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Agenus amends $10.5M notes, issues warrants at $3.25; maturity extended to July 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Extended maturity of $10.5M 2015 Notes from Feb 2025 to July 2026; interest rate raised from 8% to 9%.","Issued new C Warrants to purchase 67,500 shares at $3.25/exercise price, expiring Feb 2030.","Amended A and B Warrants for 97,500 shares: extended expiration to Feb 2030, exercise price reset to $3.25.","Obligation secured by subordinate mortgage on properties owned by subsidiary Agenus West, LLC.","Expects to address remaining $2.5M payment of 2015 Notes via a new financing in the near term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169755,"accession_number":"0000950170-25-017028","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Agenus receives termination notice from Incyte for LAG-3/TIM-3 license; rights revert to Agenus","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Incyte terminates License Agreement effective Feb 4, 2026; all rights to LAG-3 and TIM-3 revert to Agenus.","Incyte previously terminated OX40 (Oct 2023) and GITR/undisclosed (May 2024) programs.","Agenus will evaluate future opportunities, including internal development or new partnerships.","Termination follows Incyte's July 2024 announcement to discontinue LAG-3 and TIM-3 development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186808,"accession_number":"0000950170-24-133532","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2024-12-05T23:59:59+00:00","items":["2.05","9.01"],"status":"ready","headline":"Agenus strategic realignment: 60% annual cost cut, $100M cash burn target, workforce reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agenus will reduce annual expenditures by 60% and target a cash burn of $100 million for fiscal year 2025.","Workforce reduction with severance costs estimated at approximately $1.1 million; charges expected in Q1 2025.","Company will focus resources on lead program botensilimab/balstilimab (BOT/BAL) for MSS CRC and other cancers.","Agenus secured a $22M mortgage on real estate assets to support operational flexibility during restructuring."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186807,"accession_number":"0000950170-24-131263","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2024-11-27T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Agenus secures $22M mortgage and announces realignment: 60% cost cut, FY25 cash burn ~$100M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$22M non-amortizing mortgage backed by Berkeley CMC facility and Vacaville land; net proceeds $20M after costs and reserve.","Interest 12% Year 1, 13% Year 2, paid 50% cash and 50% common stock; 153,003 shares issued as first month interest and fees.","Strategic Operational Realignment: 60% reduction in external expenditures; CMC transitioned to fee-for-service business.","FY 2025 cash burn projected at ~$100M, pending finalization of additional strategic transactions.","Focus on botensilimab/balstilimab (BOT/BAL) in MSS colorectal cancer for late-stage development and registration pathways."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186806,"accession_number":"0000950170-24-124543","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agenus Q3 2024 net loss $67.2M, cash $44.8M; BOT/BAL shows MSS CRC promise","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $44.8M at Sept 30, 2024 (vs $76.1M Dec 2023); raised $7.1M via ATM post-quarter.","Q3 2024 revenue $25.1M (non-cash); net loss $67.2M; cash used in ops 9M 2024 $129.7M (down from $183.8M YoY).","BOT/BAL combination shows unprecedented outcomes in neoadjuvant MSS CRC (ESMO GI 2024) and advanced sarcomas (ESMO 2024).","Strategic initiatives: real estate monetization discussions advancing; near-term transaction expected to deliver substantial resources.","EMA agreement on dose selection and trial design for Phase 3 study in MSS CRC."],"consensus_eps_estimate":null,"consensus_eps_actual":-8.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":76626000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186804,"accession_number":"0000950170-24-124055","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K/A","filed_at":"2024-11-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Agenus appoints Thomas L. Harrison as chair of Audit and Finance Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thomas L. Harrison appointed to Audit and Finance Committee as chair and to Corporate Governance and Nominating Committee, effective Nov 5, 2024.","Committee assignments follow Harrison's earlier Board appointment disclosed on Aug 8, 2024.","No other changes to Board composition or committee membership were reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186805,"accession_number":"0000950170-24-121443","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Ulf Wiinberg resigns from Agenus board, stays as senior advisor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ulf Wiinberg resigned as director effective 5:00 p.m. ET on November 5, 2024.","Wiinberg will continue to advise the company on an ad hoc basis as senior advisor.","Resignation was not due to any disagreement with Agenus operations, policies or practices.","Chairman and CEO Garo H. Armen signed the 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203345,"accession_number":"0001193125-24-197046","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","5.02","8.01","9.01"],"status":"ready","headline":"Agenus Q2 net loss $54.8M, advances BOT/BAL in CRC; appoints director; files ATM for up to 13.8M shares","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss $54.8M, revenue $23.5M (incl $22.6M non-cash royalty); cash $93.7M at June 30 vs $76.1M Dec 31.","BOT/BAL in r/r MSS CRC: RECIST ORR 19.4% in selected cohort; 90% 6-month OS; FDA discouraged AA submission; plan to refile with mature data.","NEST-2 neoadjuvant CRC: 56% (5/9) patients achieved complete pathologic responses; 78% had ≥50% tumor reduction.","Appointed Thomas L. Harrison to Board as Class III director; granted option for 7,500 shares vesting over 3 years.","Filed prospectus supplement for ATM offering of up to 13,843,015 shares under existing B. Riley sales agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":51514000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203344,"accession_number":"0000950170-24-089932","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"BMS terminates AGEN1777 license; Agenus regains rights to TIGIT bispecific antibody","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BMS voluntarily terminates AGEN1777 license agreement effective Jan 26, 2025, as part of strategic pipeline realignment.","Agenus received $200M upfront plus $20M (Phase 1) and $25M (Phase 2) milestone payments from BMS since 2021.","No early termination penalties; Agenus gets exclusive, royalty-free license to BMS know-how and patent rights for AGEN1777.","BMS will assign all regulatory registrations and approvals for AGEN1777 back to Agenus.","Agenus plans to explore further development or relicensing of AGEN1777, now with safety and clinical activity data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219719,"accession_number":"0000950170-24-074231","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Agenus appoints Jennifer Buell to Board of Directors, stresses BOT/BAL BLA filing","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Jennifer Buell appointed to Agenus Board effective June 11, 2024.","Buell remains President/CEO of MiNK Therapeutics and Chairman of Agenus Executive Council.","Priority is to guide BOT/BAL program toward Biologics License Application submission this year.","Brings 27+ years biopharma experience; previously served as President & COO of Agenus.","No committee assignments; previously granted options for 37,500 shares (2023 and 2024)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219718,"accession_number":"0000950170-24-073614","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Agenus stockholders approve all five proposals at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Susan Hirsch elected as Class III director with 9,258,873 for, 1,018,060 withheld.","Amendment to 2019 Equity Incentive Plan approved: 7,717,389 for, 2,466,405 against.","Deferred compensation plan share authorization increased from 38,750 to 63,750 shares, approved 9,009,980 for.","Non-binding advisory vote on executive compensation approved: 8,811,608 for, 1,193,315 against.","Ratification of KPMG as auditor approved (13,609,986 for); company will conduct advisory vote annually."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219717,"accession_number":"0000950170-24-066545","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["2.01"],"status":"ready","headline":"Agenus closes $75M sale of royalty and milestone rights to Ligand","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Received $75M on May 30, 2024, for sale of milestone and royalty rights to Ligand Pharmaceuticals.","Sold 31.875% of development/regulatory/commercial milestone payments under five license agreements with BMS, Incyte, Merck, UroGen, Gilead.","Sold 18.75% of royalties from those agreements and 2.625% synthetic royalty on botensilimab/balstilimab net sales.","Transaction closed May 29, 2024; proceeds net of certain expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219716,"accession_number":"0000950170-24-053952","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agenus reports Q1 net loss $63.5M; announces $100M royalty financing with Ligand","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss narrowed to $63.5M ($3.04/shr) from $70.9M ($4.31/shr) a year ago; revenue $28M.","Cash and equivalents $52.9M at March 31, 2024, vs $76.1M at Dec 31, 2023; Q1 cash burn $38.2M.","Signed $100M royalty financing with Ligand ($75M initial + $25M option) to fund BOT/BAL launch readiness.","BOT/BAL Phase 1b in r/r MSS CRC NLM (n=77): 23% ORR, median OS 21.2 months, 12-month OS 71%.","Regained Nasdaq compliance after 20:1 reverse stock split in Q1 2024; plan BLA submission for BOT/BAL in H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219715,"accession_number":"0000950170-24-053949","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Agenus signs $100M royalty financing with Ligand; $75M upfront for BOT/BAL and partner programs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ligand pays $75M at closing for 18.75% of royalties and 31.875% of milestones on six partnered oncology programs, plus 2.625% royalty on BOT/BAL net sales.","Ligand has option to invest additional $25M on same terms; Agenus may syndicate up to $125M more, bringing total potential to $200M.","Warrant issued to Ligand for 867,052 shares of AGEN common stock at $17.30, exercisable until May 6, 2029.","Funds will support BOT/BAL confirmatory Phase 3 trial in r/r MSS CRC liver metastases-negative and launch readiness activities.","Covered programs include BMS-986442, AGEN2373 (Gilead), INCAGN2385/2390 (Incyte), MK-4830 (Merck), and UGN-301 (UroGen)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219714,"accession_number":"0001193125-24-088492","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2024-04-05T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Agenus shareholders approve 1-for-20 reverse stock split effective April 12, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio 1-for-20; effective 12:01 a.m. ET on April 12, 2024.","Approved at April 3 special meeting: 230.6M for, 58.6M against, 0.5M abstain.","Post-split common stock will trade under new CUSIP 00847G 804.","Stockholders of record as of Feb 9, 2024 were entitled to vote; quorum of 289.7M shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239501,"accession_number":"0000950170-24-031148","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agenus reports FY2023 net loss of $257M, revenue $156M; BOT/BAL data in CRC shows 24% ORR","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 revenue $156M, net loss $257M ($0.69 EPS); Q4 revenue $84M, net loss $49M ($0.13 EPS).","Ended 2023 with $76.1M cash; received $25M milestone from BMS in Jan 2024.","BOT/BAL in refractory MSS mCRC NLM: 24% ORR (vs 1-6% SOC), 12-month OS rate 74%.","Phase 2 topline data expected 2H2024; Fast Track designation granted.","Advancing monetization of non-strategic assets; potential $100-200M cash proceeds; partnership discussions ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239500,"accession_number":"0000950170-24-015604","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Agenus proposes 1-for-20 reverse stock split to regain Nasdaq $1 compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1:20 ratio proposed to lift share price above $1 Nasdaq minimum.","Special shareholder meeting set for April 3, 2024 to vote on the split.","Company plans BLA submission for metastatic colorectal cancer with potential 2025 launch.","Also exploring monetization of royalty assets and real estate to strengthen finances.","Engaged in discussions with pharmaceutical companies for potential cash infusions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239499,"accession_number":"0000950170-24-009147","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2024-01-31T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Agenus receives $25M milestone payment from Bristol Myers Squibb for BMS-986442 trial progress","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$25M payment received Jan 30, 2024, under global licensing agreement with BMS.","Triggered by dosing of first patient in phase 2 dose expansion of CA115-001 trial of BMS-986442.","This is the second development milestone under the agreement; first achieved previously.","Payment was received on January 30, 2024, as confirmed by the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257033,"accession_number":"0000950170-23-069051","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2023-12-08T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Agenus receives Nasdaq deficiency notice for bid price below $1.00; has 180 days to cure","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On Dec 4, 2023, Nasdaq notified Agenus that its common stock's closing bid price was below $1.00 for 31 consecutive business days.","Company has until June 3, 2024 to regain compliance by maintaining a $1.00+ closing bid price for 10 consecutive business days.","If not cured by June 3, Agenus may be eligible for an additional 180-day extension subject to meeting other listing standards.","Company is confident in resolving the deficiency; reverse stock split is under consideration but not the primary focus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257032,"accession_number":"0001157523-23-001659","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agenus Q3 net loss $64.5M; cash falls to $106.3M; BLA for botensilimab planned mid-2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $64.5M for Q3 2023, compared to $56.7M in Q3 2022; nine-month loss $208.9M.","Cash, equivalents, and short-term investments $106.3M at Sep 30, down 45% from $193.4M at Dec 31, 2022.","Total revenue Q3 $24.3M, up 7% YoY; driven by non-cash royalty revenue of $20.4M.","BLA submission for botensilimab/BAL in MSS CRC planned mid-2024; milestone payment from BMS partnership expected by end of 2023.","Pursuing non-dilutive financing: selling non-strategic assets and partial milestone/royalty sales, expected to close by H1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":72513000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274367,"accession_number":"0001157523-23-001357","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2023-08-23T23:59:59+00:00","items":["2.05","9.01"],"status":"ready","headline":"Agenus cuts workforce 25%, pauses non-core programs to focus on BOT/BAL","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~25% expected to save $2.8M by year-end; severance cost ~$1.4M.","Total savings of ~$40M by end of 2023 from halting non-BOT/BAL preclinical and clinical programs.","Partner-funded programs unaffected; first BOT/BAL regulatory filing targeted in 2024.","Restructuring supports sped-up registration and commercialization of lead immunotherapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274366,"accession_number":"0001157523-23-001274","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agenus Q2 2023 net loss $73.4M; bot/bal combo mOS 20.9 months in CRC, FDA Fast Track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $25.3M, net loss $73.4M ($0.20 EPS); cash $157.6M at June 30, down from $193.4M at Dec 2022.","Bot/bal combo in 3L+ Non-MSI-H CRC: mOS 20.9 months vs 12.9 SOC; ORR 23% vs 2.8%; FDA Fast Track granted.","ACTIVATE Phase 2 CRC and melanoma trials on target to fully enroll by end of 2023; BLA submission planned in 2024.","AGEN2373 monotherapy shows clinical responses in prostate, ampullary, vulvar cancers; first CD137 agonist with no hepatic toxicity.","Leadership appointments: Robin Taylor (CCO), Homa Yeganegi (Chief Product Strategy & Global Medical Affairs), Stephanie Fagan (CCO)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":48198000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291610,"accession_number":"0001193125-23-167911","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Agenus stockholders elect directors, approve ESPP share increase to 2M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All three Class II director nominees elected: Garo H. Armen, Susan Hirsch, Ulf Wiinberg (each >190M for, 0 against).","Amendment to 2019 ESPP approved (189.7M for, 13.7M against), doubling authorized shares from 1M to 2M.","Non-binding advisory vote on executive compensation passed (181.3M for, 19.2M against, 3.8M abstain).","Ratification of KPMG as auditor for FY2023 approved (245.1M for, 5.8M against).","Stockholders recommended annual frequency for future advisory votes on exec compensation; company will hold annual votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291609,"accession_number":"0001157523-23-000779","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agenus Q1 net loss $70.9M; botensilimab combo shows 63% 12-month OS in colorectal cancer","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $22.9M, net loss $70.9M ($0.22 EPS) vs loss $50.6M ($0.19 EPS) year ago.","Cash & investments $189.2M at March 31; raised $13.6M in ATM sales post-quarter.","Botensilimab/balstilimab: 63% 12-month OS in non-MSI-H CRC (vs 25% SOC); 33% ORR in platinum-resistant ovarian cancer.","FDA granted Fast Track for botensilimab/balstilimab in non-MSI-H/dMMR mCRC without active liver metastases.","Distributed ~5M MiNK shares (NASDAQ: INKT) as dividend to AGEN shareholders on May 1, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":22902000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291608,"accession_number":"0000950170-23-013950","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2023-04-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Agenus declares stock dividend of MiNK shares at 0.0146 per share; payable May 1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dividend of 5,000,000 MiNK shares distributed May 1, 2023, to AGEN holders of record Apr 17, 2023.","Ratio: 0.0146 MiNK shares per AGEN share; cash in lieu of fractional shares at $2.21 per share.","Dividend may be taxable as ordinary income to extent of earnings; backup withholding applies to non-corporate holders.","Non-U.S. holders subject to 30% withholding unless reduced rate via W-8 forms; corporate holders may claim dividends-received deduction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312389,"accession_number":"0001193125-23-084699","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2023-03-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Agenus declares dividend of 5M shares of MiNK Therapeutics to shareholders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Record date April 17, 2023; payment no earlier than April 27 and no later than May 17, 2023.","Pro rata distribution; no fractional shares; cash in lieu based on MiNK closing price on record date.","CEO Garo Armen says dividend demonstrates commitment to delivering additional shareholder value.","MiNK to present updated clinical data for agenT-797 at AACR Annual Meeting April 14-19, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312388,"accession_number":"0001171843-23-001657","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2023-03-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agenus Q4 net loss $74M; botensilimab shows 23% ORR in MSS CRC, 50% in NSCLC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 revenue $28.4M, net loss $74.1M ($0.24/sh); FY22 revenue $98M, net loss $230.7M ($0.78/sh).","Cash & short-term investments $193M at Dec 31, 2022, down from $307M a year earlier.","Botensilimab/balstilimab combo: 23% ORR in MSS CRC (70 evaluable), 50% ORR in PD-(L)1 refractory NSCLC (8 evaluable).","Phase 3 confirmatory trial in MSS CRC expected in 2023; randomized Phase 2 ACTIVATE studies ongoing.","Potential future milestones from collaborations up to $2.7B; nine new partner trials launched in 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330937,"accession_number":"0000950170-22-027012","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2022-12-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Wadih Jordan resigns from Agenus board, effective Dec 31, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Wadih Jordan notified resignation on Dec 21, 2022, effective Dec 31, 2022.","Jordan served approximately 20 years as a board member.","Resignation is a full retirement; no disagreement with company operations.","No replacement director has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330936,"accession_number":"0000950170-22-025998","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2022-12-02T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Agenus extends $13M note maturity to 2025; terminates old warrants, issues new warrants at $2.84","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Extended maturity of $13M senior subordinated notes from Feb 2023 to Feb 2025.","Terminated warrants for 1.95M shares (1.3M from 2015, 650k from 2020).","Issued new warrants for 1.95M shares, expiring 2026 and 2028, exercise price $2.84 (15% premium to 30-day avg).","New warrants issued as unregistered securities under Section 4(2) of Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330935,"accession_number":"0001171843-22-007211","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agenus reports Q3 net loss $56.7M, cash $218.2M; botensilimab Phase 2 trials initiated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2022 net loss $56.7M ($0.19/sh) vs prior-year net income; revenue $22.8M, down from $253M largely due to prior milestone.","Cash and investments $218.2M vs $306.9M at Dec 2021; cash used in operations $32.2M in Q3.","Initiated Phase 2 ACTIVATE trials of botensilimab in advanced MSS colorectal cancer and melanoma.","Expanded leadership: Patricia Carlos named Chief Regulatory, Quality & Safety Officer; Todd Yancey as Senior Clinical Advisor.","Partner programs advancing: BMS, Merck, Incyte ongoing Phase 2/1 trials for discovered assets."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":69638000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348486,"accession_number":"0001171843-22-005503","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agenus Q2 net loss narrows to $49M; botensilimab shows 24% ORR in MSS CRC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $49.2M ($0.17/share) vs $84.0M ($0.37) in Q2 2021; revenue $20.9M (up from $10.7M).","Cash & investments $238M at June 30, 2022, down from $307M at Dec 31, 2021.","Botensilimab/balstilimab combo achieved 24% ORR and 73% DCR in 41 heavily pretreated MSS CRC patients.","Phase 2 randomized trials in MSS CRC, melanoma, and pancreatic cancer to start later this year.","First patient dosed in Phase 1 study of AGEN1571 (anti-ILT2) in advanced solid tumors."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":46867000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348485,"accession_number":"0001193125-22-213607","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2022-08-05T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Agenus increases authorized common shares from 400M to 800M after stockholder approval","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized shares of common stock doubled to 800,000,000 from 400,000,000.","Stockholders approved the amendment at August 4, 2022 special meeting: 173,447,837 for, 28,448,854 against, 698,341 abstain.","Certificate of Amendment filed with Delaware Secretary of State on August 5, 2022, effective immediately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365177,"accession_number":"0001193125-22-173826","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2022-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Agenus shareholders elect directors, approve equity plan amendments at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Brian Corvese re-elected as Class I director with 127.5M for, 15.0M withheld; Timothy R. Wright with 97.6M for, 44.9M withheld.","Amendment to Directors' Deferred Compensation Plan approved (129.7M for, 12.5M against) increasing authorized shares from 575,000 to 775,000.","Amendment to 2019 Equity Incentive Plan approved (124.4M for, 17.8M against) increasing authorized shares from 26M to 41M.","Ratification of KPMG as independent auditor for FY2022 approved (149.4M for, 42.9M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365176,"accession_number":"0001171843-22-003483","cik":1098972,"company_name":"AGENUS INC","ticker":"AGEN","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agenus Q1 2022 net loss $51M; cash $263M; botensilimab to Phase 2; Gilead $5M milestone","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $51M ($0.19/share) vs $54M ($0.27/share) YoY; revenue $26M (up from $12M).","Cash and short-term investments $263M, down from $307M at Dec 31, 2021; cash used in ops $52M.","Botensilimab advancing to Phase 2 trials in colorectal, melanoma, pancreatic cancers; data in Q3 2022.","AGEN1571 (ILT2) Phase 1 to start; AGEN2373 milestone of $5M from Gilead (up to $570M potential).","Cost containment measures initiated to reduce operating expenses in coming quarters."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":25941000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":140543202.9325513,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-05-10T23:59:59+00:00|365176"}